For patients with non-acute promyelocytic leukemia (APL), platelet count at diagnosis has a predictive value for therapeutic outcome, according to a study published in BMC Cancer. Researchers sought to analyze the link between platelet count at diagnosis and therapeutic outcome in patients with non-APL. In a study of 330 patients newly diagnosed with non-APL, they evaluated the link between genetic mutations and platelet count at diagnosis. Following chemotherapy or allogeneic hematopoietic stem cell transplantation, the effect of platelet count on minimal residual disease status, complete remission, and relapse-free survival were assessed. Patients with CEBPA biallelic mutations or t(8;21)(q22; q22) translocation had a lower platelet count at diagnosis, while patients with DNMT3A mutations revealed a higher platelet count. Additionally, patients with non-APL and high platelet counts (>65×09/L) responded worse to induction chemotherapy and had a worse relapse-free survival than those with a low platelet count.
